Cosmos Health Inc.
COSM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for COSM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · COSM
Cosmos Health Inc. is an international healthcare company with a proprietary line of nutraceuticals and a distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications, and medical devices, operating through a lean, decentralized model focused on acquisitions and manufacturing expansion.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 7 clinical trials · 3 catalysts for Cosmos Health Inc..
Cosmos Health Inc. is an international healthcare company with a proprietary line of nutraceuticals and a distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications, and medical devices, operating through a lean, decentralized model focused on acquisitions and manufacturing expansion.
- Cash and equivalents of $2.4M as of 2026-06-30 [sec].
- Total revenue of $19.0M and net loss of -$6.1M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $26.2M and total debt of $5.2M as of 2026-06-30 [sec].
- Company strategy includes optimizing its generics business, expanding manufacturing (CMO/CDMO), and leveraging global networks to enter new markets such as the UAE and GCC countries [sec_mda · as of 2026-08-18].
- Acquired an AI-driven drug repurposing platform called 'Cloudscreen®' to address major health challenges [sec_mda · as of 2026-08-18].
What works
- The company has a diversified business model encompassing proprietary nutraceuticals, generic pharmaceuticals, and manufacturing services (CMO/CDMO), which provides multiple revenue streams [sec_mda · as of 2026-08-18].
- Strategic acquisitions have strengthened core product technology and added manufacturing, marketing, and R&D capabilities [sec_mda · as of 2026-08-18].
- The company is actively expanding its global network into new regions (e.g., UAE, GCC, Eastern Europe) to grow market share [sec_mda · as of 2026-08-18].
What to weigh
- The company has a going concern uncertainty, with revenues insufficient to sustain operations and doubts about meeting obligations over the next 12 months [sec_mda · as of 2024-08-05].
- Net loss of -$6.1M and relatively low cash reserves of $2.4M as of 2026-06-30 indicate ongoing financial strain [sec].
- The company may not be able to obtain additional financing on acceptable terms, which could force delays or reductions in R&D and product portfolio [sec_mda · as of 2026-08-18].
From the filings
Quoted directly from source documents.
Company description as an international healthcare company with proprietary nutraceuticals and distributor of pharmaceuticals.
“We are an international healthcare company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices.”
SEC MD&A · November 14, 2024
Going concern uncertainty due to insufficient revenues.
“The Company's revenues are not able to sustain its operations, and concerns exist regarding the Company's ability to meet its obligations as they become due.”
SEC MD&A · August 5, 2024
Acquisition of AI-driven drug repurposing platform Cloudscreen.
“Finally, our recently acquired AI-driven drug repurposing platform "Cloudscreen®", aims to address major health challenges in various treatment areas.”
SEC MD&A · August 18, 2026
Risk of not obtaining financing and potential impact on R&D.
“If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product port”
SEC MD&A · August 18, 2026
Catalyst timeline
- 2027-09-30 · Phase3_Topline · blinatumomab — Phase 3 Topline: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patient — Topline results from a Phase 3 trial of blinatumomab in combination with chemotherapy.
- 2030-12-01 · Phase3_Topline — Phase 3 Topline: An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Pat — Topline results from a Phase 3 pilot study of chemotherapy and tyrosine kinase inhibitors with blinatumomab.
- 2031-04-28 · Phase3_Topline · immuno-oncology — Phase 3 Topline: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology — Topline results from a Phase 3 randomized trial comparing standard therapy with immuno-oncology.
Risks & what to watch (3)›
Key risks
- Going concern uncertainty — Revenues are insufficient to sustain operations, raising substantial doubt about ability to meet obligations for 12 months [sec_mda · as of 2024-08-05].
- Financing risk — May not obtain additional capital on acceptable terms, which could delay or reduce R&D and product portfolio [sec_mda · as of 2026-08-18].
- Dependence on key individuals and products — Company is subject to risks typical of smaller commercial companies, including dependence on key individuals and products [sec_mda · as of 2024-08-05].
What to watch
- Ability to secure additional financing or strategic partnerships to address going concern [sec_mda · as of 2026-08-18].
- Progress of manufacturing expansion and entry into new markets like UAE and GCC [sec_mda · as of 2026-08-18].
- Development and commercialization of the Cloudscreen AI drug repurposing platform [sec_mda · as of 2026-08-18].
- Upcoming Phase 3 topline results for blinatumomab trials scheduled in 2027, 2030, and 2031 [upcoming catalysts].
Sources: SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Cosmos Health Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cosmos Health Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
22.2 months
D/E 1.97 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
3 upcoming, next in ~396d
5 buys · 0 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
22
Total value held
$584K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 390,500 | $124K |
| citadel advisors llc | 336,606 | $107K |
| geode capital management, llc | 318,111 | $101K |
| vanguard capital management llc | 280,014 | $89K |
| blackrock, inc. | 267,797 | $85K |
| vanguard fiduciary trust co | 95,735 | $30K |
| state street corp | 45,243 | $14K |
| xtx topco ltd | 40,477 | $13K |
| northern trust corp | 20,554 | $7K |
| susquehanna international group, llp | 17,734 | $6K |
Showing top 10 of 22 institutional holders of Cosmos Health Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.5%
- Days to cover
- 0.4
- Shares short
- 622,196
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
COSM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cosmos Health Inc.?
Cosmos Health Inc. is an international healthcare company with a proprietary line of nutraceuticals and a distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications, and medical devices, operating through a lean, decentralized model focused on acquisitions and manufacturing expansion.
What is Cosmos Health Inc.'s next catalyst?
Cosmos Health Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patient" — expected September 30, 2027.
Who is the CEO of Cosmos Health Inc.?
Mr. Grigorios Siokas is the chief executive officer of Cosmos Health Inc. (COSM).
Where is Cosmos Health Inc. headquartered?
Cosmos Health Inc. (COSM) is headquartered in Thessaloniki, Greece.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.